Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study

Inal, A.; Kos, F.; Algin, E.; Yildiz, R.; Berk, V.; ÜNEK, İLKAY; Colak, D.; Kucukoner, M.; ELKIRAN, EMİN; Helvaci, K.; Geredeli, C.; Dane, F.; Balakan, O.; Kaplan, M.; Durnali, A.; Harputoglu, H.; Goksel, G.; Ozdemir, N.; Buyukberber, S.; Gumus, M.; Ozkan, M.; Benekli, M.; Isikdogan, A.

Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study

Copy For Citation

Inal A., Kos F. T., Algin E., Yildiz R., Berk V., ÜNEK İ. T., ...More

JOURNAL OF BUON, vol.17, no.1, pp.102-105, 2012 (SCI-Expanded)

Publication Type: Article / Article
Volume: 17 Issue: 1
Publication Date: 2012
Journal Name: JOURNAL OF BUON
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.102-105
Keywords: cancer, gemcitabine, pancreas, prognosis, SINGLE-AGENT GEMCITABINE, RANDOMIZED PHASE-III, ADENOCARCINOMA, INDEX
Dokuz Eylül University Affiliated: Yes

Abstract

Purpose: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyse prognostic factors for OS in advanced pancreatic cancer patients treated with first-line palliative chemotherapy with gemcitabine alone or gemcitabine plus cisplatin.